- Home
- TNYA vs MNPR Comparison
TNYA vs MNPR Comparison
Compare TNYA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- MNPR
- Stock Information
- Founded
- TNYA 2016
- MNPR 2014
- Country
- TNYA United States
- MNPR United States
- Employees
- TNYA N/A
- MNPR N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- MNPR Health Care
- Exchange
- TNYA Nasdaq
- MNPR Nasdaq
- Market Cap
- TNYA 119.2M
- MNPR 113.5M
- IPO Year
- TNYA 2021
- MNPR 2019
- Fundamental
- Price
- TNYA $1.43
- MNPR $24.98
- Analyst Decision
- TNYA Strong Buy
- MNPR Strong Buy
- Analyst Count
- TNYA 4
- MNPR 4
- Target Price
- TNYA $17.33
- MNPR $38.50
- AVG Volume (30 Days)
- TNYA 6.3M
- MNPR 56.8K
- Earning Date
- TNYA 11-06-2024
- MNPR 11-08-2024
- Dividend Yield
- TNYA N/A
- MNPR N/A
- EPS Growth
- TNYA N/A
- MNPR N/A
- EPS
- TNYA N/A
- MNPR N/A
- Revenue
- TNYA N/A
- MNPR N/A
- Revenue This Year
- TNYA N/A
- MNPR N/A
- Revenue Next Year
- TNYA N/A
- MNPR N/A
- P/E Ratio
- TNYA N/A
- MNPR N/A
- Revenue Growth
- TNYA N/A
- MNPR N/A
- 52 Week Low
- TNYA $0.99
- MNPR $1.55
- 52 Week High
- TNYA $7.01
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- TNYA 37.10
- MNPR 54.35
- Support Level
- TNYA $1.33
- MNPR $21.00
- Resistance Level
- TNYA $1.63
- MNPR $26.52
- Average True Range (ATR)
- TNYA 0.15
- MNPR 2.22
- MACD
- TNYA 0.01
- MNPR -0.15
- Stochastic Oscillator
- TNYA 18.92
- MNPR 65.19
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.